GlassScriptPhysician profile
Ashok D Sastry
NPI 1255372199
$4,734.92
in general payments reported to CMS, 2019-2025
28 companies · $960 in 2025
The $960 reported for 2025 was more than what 77% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $553 · 2020: $1,553 · 2021: $25.32 · 2022: $122 · 2023: $870 · 2024: $652 · 2025: $960.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,482.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,481.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Travere Therapeutics, INC. | $1,792.09 | 2020-2025 | |
| Calliditas Therapeutics US INC. | $257.58 | 2023-2025 | Tarpeyo |
| Otsuka America Pharmaceutical, INC. | $205.11 | 2019-2025 | Jynarque |
| Fresenius USA Marketing, INC. | $200.63 | 2019-2025 | Velphoro, Velphoro |
| Bayer Healthcare Pharmaceuticals INC. | $200.61 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $186.44 | 2023-2025 | |
| Amgen INC. | $170.51 | 2023-2025 | Krystexxa, Tavneos, Parsabiv |
| Astrazeneca Pharmaceuticals LP | $147.35 | 2019-2025 | Wainua, Lokelma, Farxiga |
| Baxter Healthcare | $141.83 | 2019-2023 | Renal - Pd |
| Mallinckrodt Hospital Products INC. | $130.84 | 2023-2025 | Terlivaz |
| Mallinckrodt Enterprises LLC | $129.40 | 2019 | |
| Horizon Therapeutics Plc | $128.42 | 2019-2023 | Krystexxa |
| Akebia Therapeutics INC | $116.51 | 2019-2025 | Auryxia, Vafseo |
| Ardelyx, INC. | $113.90 | 2024-2025 | Ibsrela |
| Boehringer Ingelheim Pharmaceuticals, INC. | $111.60 | 2023-2025 | Jardiance |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $94.94 | 2023-2025 | Jardiance |
| Alexion Pharmaceuticals, INC. | $85.10 | 2019-2020 | |
| Vifor Pharma, INC. | $84.30 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $75.79 | 2023-2024 | Gattex |
| Novo Nordisk INC | $72.21 | 2023-2025 | Ozempic, Rybelsus |
| Shire North American Group INC | $49.30 | 2019 | |
| Alnylam Pharmaceuticals INC. | $46.84 | 2023-2024 | Givlaari |
| Scpharmaceuticals INC. | $42.75 | 2025 | |
| Aurinia Pharma U.S., INC. | $42.36 | 2023-2024 | Lupkynis |
| Opko Pharmaceuticals, LLC | $37.87 | 2019-2023 | Rayaldee |
| Glaxosmithkline, LLC. | $27.03 | 2023 | Benlysta |
| Nuwellis, INC. | $24.25 | 2025 | Aquadex Smartflow Console |
| Apellis Pharmaceuticals, INC. | $19.36 | 2025 | Empaveli |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashok Sastry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.